SG Americas Securities LLC decreased its holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK – Free Report) by 89.8% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,625 shares of the company’s stock after selling 75,724 shares during the period. SG Americas Securities LLC’s holdings in Scholar Rock were worth $424,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. IFP Advisors Inc lifted its stake in Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after purchasing an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Scholar Rock during the fourth quarter valued at about $30,000. Summit Securities Group LLC bought a new position in shares of Scholar Rock during the fourth quarter valued at about $31,000. EverSource Wealth Advisors LLC increased its holdings in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after buying an additional 525 shares during the period. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of Scholar Rock in the fourth quarter worth about $44,000. Institutional investors own 91.08% of the company’s stock.
Insider Transactions at Scholar Rock
In other news, Director Michael Gilman sold 2,544 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $53.87, for a total transaction of $137,045.28. Following the transaction, the director directly owned 59,511 shares of the company’s stock, valued at approximately $3,205,857.57. The trade was a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Katie Peng sold 5,446 shares of Scholar Rock stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $293,430.48. Following the completion of the sale, the director owned 34,301 shares in the company, valued at approximately $1,848,137.88. This trade represents a 13.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 80,640 shares of company stock worth $4,070,357. Corporate insiders own 13.30% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Report on SRRK
Scholar Rock Stock Performance
Scholar Rock stock opened at $56.03 on Thursday. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. The firm has a market cap of $6.71 billion, a P/E ratio of -15.61 and a beta of 0.67. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $57.80. The firm has a 50-day moving average of $48.99 and a 200-day moving average of $46.85.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter in the prior year, the firm posted ($0.67) earnings per share. Sell-side analysts expect that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.
Scholar Rock Profile
Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.
The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).
Featured Articles
- Five stocks we like better than Scholar Rock
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.
